What does this research mean for the field?

Daily use of 81 mg aspirin does not increase the rate of pseudoarthrosis or perioperative complications in patients undergoing single-level posterior or transforaminal lumbar interbody fusion. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

To evaluate the association between daily low-dose aspirin (81 mg) use and pseudoarthrosis rates after single-level posterior or transforaminal lumbar interbody fusion.

August 27, 2026British Journal of Neurosurgery

Does low-dose aspirin use influence rates of pseudoarthrosis after posterior and transforaminal lumbar interbody fusion? A propensity-matched study

View Full Paper

Ask AI

Bookmark

Authors

KKKevin T. KimUniversity of Maryland, Baltimore ZKZiam KhanUniversity of Maryland, Baltimore JSJoseph StainsUniversity of Maryland, Baltimore

Discussion

Member takes

Implication

Retrospective matched cohort study finds lower pseudoarthrosis rates in lumbar fusion patients taking low-dose aspirin, suggesting daily aspirin does not impair bone healing.

Key Points

To evaluate the association between daily low-dose aspirin (81 mg) use and pseudoarthrosis rates after single-level posterior or transforaminal lumbar interbody fusion.
A retrospective cohort study was conducted using the multi-institutional TriNetX database encompassing 71 healthcare organizations.
Patients undergoing single-level PLIF or TLIF were categorized by daily 81 mg aspirin use versus no aspirin (active within 3 months perioperatively) and 1:1 propensity score matched on demographic and frailty variables.
Primary outcomes included pseudoarthrosis at 6 months to 5 years, reoperations within 5 years, and 30-day complications.
Patients receiving 81 mg aspirin (n = 2,936) showed significantly lower rates of reported pseudoarthrosis at all time points (6 months, 1 year, 2 years, 3 years, and 5 years) compared to matched controls.
No significant differences occurred in reoperation rates at any time point or in 30-day adverse outcomes, including post-operative hematoma, transfusions, surgical site infections, readmissions, and emergency visits.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe99110c91c1e9262135e https://doi.org/10.1080/02688697.2026.2723109

View Full Paper

Ask AI

Bookmark

Implication

Retrospective matched cohort study finds lower pseudoarthrosis rates in lumbar fusion patients taking low-dose aspirin, suggesting daily aspirin does not impair bone healing.

Does low-dose aspirin use influence rates of pseudoarthrosis after posterior and transforaminal lumbar interbody fusion? A propensity-matched study

Discussion

Member takes

Implication

Key Points

Cite This Study

Does low-dose aspirin use influence rates of pseudoarthrosis after posterior and transforaminal lumbar interbody fusion? A propensity-matched study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider